Decision makers frequently face decisions about optimal resource allocation. A model-
based economic evaluation can be used to guide decision makers in their choices by …

Digital therapeutics (DTx) are a promising way to provide safe, effective, accessible,
sustainable, scalable, and equitable approaches to advance individual and population …

Introduction The 21st century has brought about significant technological advancement,
allowing the collection of new types of data from the real world on an unprecedented scale …

Background: Real-world evidence (RWE) can reinforce clinical trial evidence in health
technology assessment (HTA). Objectives: Review HTA bodies'(HTAbs) requirements for …

Health technology assessment (HTA) decisions for pharmaceuticals are complex and
evolving. New rare disease treatments are often approved more quickly through accelerated …

Reimbursement decisions and price negotiation of healthcare interventions often rely on
health economic model results. Such decisions affect resource allocation, patient outcomes …

Most new drug approvals are based on data from large randomized clinical trials (RCTs).
However, there are sometimes contradictory conclusions from seemingly similar trials and …

Abstract Introduction The non-interventional Phase IV PROVE study (NCT03208660)
assessed retention, efficacy, safety and tolerability, and perampanel dosing in patients with …

Objectives This study aims to identify how real-world data (RWD) have been used in single
technology appraisals (STAs) of cancer drugs by the National Institute for Health and Care …

Multi-criteria decision analysis (MCDA) is a value assessment tool designed to help support
complex decision-making by incorporating multiple factors and perspectives in a …